Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 2,845 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) COO Patrick John Finn sold 2,845 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $140,400.75. Following the completion of the sale, the chief operating officer now owns 269,199 shares of the company's stock, valued at $13,284,970.65. This trade represents a 1.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00.

Twist Bioscience Trading Down 2.6 %

Shares of TWST traded down $1.40 during mid-day trading on Friday, reaching $52.30. The stock had a trading volume of 883,044 shares, compared to its average volume of 786,851. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.54. The business's fifty day moving average is $48.91 and its 200 day moving average is $46.13. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -15.47 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million during the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business's revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.75) EPS. On average, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TWST. Massachusetts Financial Services Co. MA increased its position in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company's stock worth $1,324,000 after purchasing an additional 20,035 shares during the last quarter. Barclays PLC boosted its stake in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company's stock worth $6,913,000 after buying an additional 104,420 shares during the period. FMR LLC increased its position in shares of Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company's stock valued at $9,875,000 after acquiring an additional 12,327 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company's stock worth $1,718,000 after acquiring an additional 21,357 shares during the last quarter.

Wall Street Analyst Weigh In

TWST has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Barclays decreased their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Scotiabank upped their target price on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a "sector outperform" rating in a report on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and an average target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.